Suzhou Ribo Life Science and its subsidiary Ribocure Pharmaceuticals have reported positive Phase IIa results for vortosiran in patients with chronic coronary artery disease.
Vortosiran, also known as RBD4059, is an investigational small interfering RNA therapy targeting coagulation Factor XI.
The randomised, double-blind and placebo-controlled European study evaluated multiple doses of vortosiran in patients receiving aspirin as standard-of-care treatment.
Ribo said the candidate was generally well tolerated and produced dose-dependent and sustained suppression of Factor XI activity.
Factor XI is involved in the blood-coagulation pathway and is being investigated as a therapeutic target for reducing thrombosis while potentially limiting the bleeding risks associated with existing anticoagulants.
The study represents the first reported clinical dataset evaluating repeated administration of an siRNA-mediated Factor XI inhibitor in patients with coronary artery disease, according to the company.
The results were presented during the China Pharmaceutical Innovation Conference in Shanghai.
Ribo is using the Phase IIa findings to inform the subsequent clinical-development programme for vortosiran.
